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Abstract
Background: As ART programmes in African settings expand beyond the pilot stages, adherence
to treatment may become an increasing challenge. This qualitative study examines potential
barriers to, and facilitators of, adherence to ART in a workplace programme in South Africa.
Methods: We conducted key informant interviews with 12 participants: six ART patients, five
health service providers (HSPs) and one human resources manager.
Results: The main reported barriers were denial of existence of HIV or of one's own positive
status, use of traditional medicines, speaking a different language from the HSP, alcohol use, being
away from home, perceived severity of side-effects, feeling better on treatment and long waiting
times at the clinic. The key facilitators were social support, belief in the value of treatment, belief
in the importance of one's own life to the survival of one's family, and the ability to fit ART into
daily life schedules.
Conclusion: Given the reported uncertainty about the existence of HIV disease and the use of
traditional medicines while on ART, despite a programme emphasising ART counselling, there is a
need to find effective ways to support adherence to ART even if the individual does not accept
biomedical concepts of HIV disease or decides to use traditional medicines. Additionally, providers
should identify ways to minimize barriers in communication with patients with whom they have no
common language. Finally, dissatisfaction with clinical services, due to long waiting times, should be
addressed.
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Background
The number of HIV-infected individuals receiving ART in
Sub-Saharan Africa increased from 100,000 (an estimated
2% of those requiring it) in 2003 to 1.3 million (24–33%
of those requiring it) in 2006 [1]. This has given people
living with HIV/AIDS greater hope as treatment has led to
improved survival and decreased morbidity [2,3].
Though the definition of the "sufficient" level of adher-
ence is still evolving, close adherence to ART remains
important to achieving viral suppression, reduced risk of
disease progression and better survival [4-6]. Early reports
from pilot ART programmes in African settings show high
levels of adherence to treatment [7]. However, as ART
delivery programmes grow beyond pilot phases, a focus
on maintaining these levels is essential. Given that adher-
ence is the strongest predictor of treatment success, a
clearer understanding of adherence barriers in low-
income countries providing ART is needed [8-11]. Due to
the relatively limited experience of ART use in low-income
countries, information about barriers to adherence is lim-
ited. Even more limited are qualitative studies looking not
only at who is having difficulty in adhering but also at
why. A recent systematic review of adherence reported on
only two such studies [12].
Within the existing body of literature from low-income
countries a few factors have more frequently been
reported to be associated with poor adherence. These
include structural barriers such as high cost and unavaila-
bility of drugs [13-15], and individual factors such as lack
of self efficacy for medication taking [16,17], lack of social
or family support [16,18], high anxiety, perception that
ART has a negative effect [16,17], and fear of stigma and
discrimination through disclosure of HIV status [19,20].
However, lower level of education has not consistently
been reported to be associated with poor adherence [17-
19,21].
This study was conducted in a large workplace ART pro-
gramme providing treatment in South Africa since 2002.
All services and medications were provided free of charge
to employees with HIV infection. Patients received rou-
tine care based on a standardized protocol. All patients
underwent intensive adherence counselling aimed at pre-
paring them to start taking ART. Counselling was also
offered and provided at all subsequent programme visits.
This study mirrored many public sector ART programmes
in that it offered ART to all who fulfil medical criteria
without other pre-requisites. The purpose of this study
was to qualitatively explore patient and health provider
perspectives of barriers to, and enablers of, adherence in a
workplace setting.
Methods
Design and participants
In this qualitative study we held key-informant interviews
with two groups of participants. The first group was
patients who had received ART for at least 8 weeks. We
made a special effort to interview poor adherers. Poor
adherers were classified as such if they fulfilled any of the
following criteria: reported to clinic staff any difficulties
taking treatment regularly and on time; or missed clinic
visits; and/or who had less than a 1 log drop in HIV viral
load eight weeks after ART start. The second group was
individuals involved in, or supporting the provision of
treatment and care for ART patients. All health service pro-
viders (HSPs) in the HIV wellness clinic and a mine
human resources manager were interviewed. A traditional
healer was selected in consultation with the traditional
healers' association of South Africa, specifically because
she worked in close proximity to the wellness clinic. Par-
ticipants were eligible for the study if they expressed will-
ingness to share their views on adherence to ART and were
at least 18 years of age.
Data collection
Interviews lasting 1 to 1.5 hours were conducted in the
language of the participant's choice. All interviews were
tape-recorded except two, one because of the participant's
preference and the other due to tape recorder malfunc-
tion. In both these cases detailed notes were taken. An
interpreter facilitated interviews conducted in local lan-
guages, transcribed the interviews verbatim and translated
them into English. Patients taking ART were interviewed
regarding: 1) their experience of ART and how they took
it; 2) what helped or kept them from taking ART; 3) what
they thought might help or keep other patients from tak-
ing ART. Health care providers and the human resources
manager were interviewed regarding their perceptions of
what helps and/or what keeps patients from taking ART
regularly.
Data analysis
We analysed the interview data using a thematic content
analysis approach. This approach is a comparative process
by which the various accounts gathered are compared
with each other to classify those "themes" that recur or are
common in the data set [22]. We perused initial tran-
scripts on a line-by-line basis to identify phrases and
assign content-related categories or key themes after mul-
tiple readings. Codes were developed to label key themes
in the data and to develop a coding scheme. We then ana-
lysed the content of each script using the coding scheme
to identify the most common or recurrent themes.
Ethics
Ethics approval for the study was provided by the Biomed-
ical Research Ethics Committee of the University of Kwa-BMC Public Health 2008, 8:63 http://www.biomedcentral.com/1471-2458/8/63
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Zulu-Natal (South Africa) and the Ethics Committee of
the London School of Hygiene and Tropical Medicine.
Individuals willing to participate in the study provided
written informed consent for participation.
Results
The interviews were conducted from June to July 2005
with 12 participants: six ART patients, five health service
providers (including one traditional healer), and one
company human resources manager. Four of the health
care providers were female. The six patients were all male
and they had been on ART for more than 8 weeks. Four
were classified as poor adherers.
Key barriers
Individual factors
Several individual factors were thought to lead to non-
adherence. These were alcohol use, being away from
home, fear of stigma, use of traditional medicines, and
lack of belief in the existence of HIV and/or one's own sta-
tus. Finally some participants felt that old age and illiter-
acy may also lead to poor adherence.
Most participants reported that alcohol use, being away
from the usual place of residence and fears of stigma were
potential barriers to adherence.
"Alcohol makes you forget things. I used to be taking it then
I stopped [taking alcohol]....I used to feel something after
taking tables...dizzy. Its alcohol only [that prevents patients
from taking ART]." PID 01: Patient
Both patients and health care providers reported that fear
of stigmatisation reportedly caused patients who had not
disclosed their HIV status to hide their ART or skip doses
when in the presence of others.
"Some are scared to disclose ...If a person does not disclose
to his partner he will have a problem in taking his medica-
tion, because he will have to hide ... and if they have to hide
medication ... one day you are not going to take because
you'll be scared. oh is she going to see me? Let me not take
it today. I'll take it when she has gone." PID 05: HSP
The use of traditional medicines while on ART was also
reported as a potential barrier. Both patients and provid-
ers felt that ART and traditional medicines should not be
"mixed". Some patients who reported using traditional
medicines after starting ART also said that they had
stopped treatment for the duration of traditional medi-
cine use.
"I tell the patients to take my medicine for one week and
then for the other week it must be the tablets [ART] ..." PID
09: Traditional healer
"I had a pain in my foot and the doctors could not help me
... I went to my traditional healer. She gave me something
... That is why I stopped the ART. You shouldn't mix the
two!!" PID 06: patient
Providers reported that denial of the existence of HIV or of
one's own HIV-positive status kept some patients from
taking their treatment.
"Those patients who are not adherent don't believe that
HIV is the cause of the illness. ... They believe that they are
bewitched or it's got nothing to do with the virus that's caus-
ing AIDS". PID 08: provider
A patient who did not think that HIV existed or that he
was HIV infected also reported discontinuing treatment
because he did not feel that it was always necessary.
"I don't think I have HIV ... Ahh, I am not sure [that HIV
exists] ... look at me I am fine ... I am not sick ... I have
normal people's sicknesses ... if I am sick again I'll use the
best medicine for that sickness, maybe the ART maybe
something else." PID 06: patient
Providers believed strongly that older and illiterate
patients had more difficulty understanding counselling
and instructions regarding how to take treatment and,
therefore, had more difficulty in adhering to treatment.
However, patients interviewed did not feel that age or
educational level would negatively affect their own ability
to adhere to treatment.
Disease and treatment
Feeling well and experiencing side effects were the main
disease and treatment factors reported to influence adher-
ence. Feeling well after taking treatment was reported as
both a barrier to, and a facilitator of adherence.
"After I recovered, I noticed that they [ART pills] are work-
ing and I continued. I can't stop them" PID 01: poorly
adherent patient
"Sometimes when I feel I am right, I don't take them [ART
pills]" PID 11: poorly adherent patient
A patient who reported experiencing "severe" side-effects,
including hallucinations and insomnia, which affected
his ability to work, discontinued ART in the early stages of
treatment.
"It [ART] just gave me problem from the first time after
using it ... I told them [HSPs] no, I am not going to use
them again. I am going to end up not going to work because
of them ... That's how I stopped them." PID 03: patientBMC Public Health 2008, 8:63 http://www.biomedcentral.com/1471-2458/8/63
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Patient/health care provider relationship
Communication barriers were thought to contribute to
poor adherence. Providers felt that this primarily affected
patients who spoke languages different from those of their
providers.
"... Especially the [cited a specific ethnic group] don't
adhere. We try to speak their language ... sometimes he
knows a bit of my language, then I talk my language, I ask
him if he can hear me." PID 05: provider
Health system
Most patients interviewed felt that clinic waiting times
were too long. This contributed to their dissatisfaction
with clinic services and made them more likely to stop
coming to the clinic to pick up their medications.
"We leave the hostels at seven without breakfast ... You can
wait again until one o'clock. Then you can see a doctor.
You're hungry, you've been waiting, and again you're sick."
PID 12: patient
Key facilitators
The main reported facilitators of adherence were disclo-
sure, having social support and a strong belief in the value
of treatment.
However, some patients reported that despite not disclos-
ing their HIV status to their family or friends they still
relied on them for support to take treatment.
"I never told them [my family members] that I am taking
ART ... I just told them it's my TB treatment ... it was help-
ing because they always reminded me to take my tablets
before I go to bed." PID 01: patient
Some patients reported that a strong belief in the value of
treatment also helped them adhere to treatment. Addi-
tionally the two more adherent patients stressed the
importance of their future well-being for the survival of
their families and loved ones.
"Nobody reminds me of my medication. I do it on my own,
because the only thing I think of if I don't take my treat-
ment is death ... how were they [family members] going to
survive if I was dead ... I can't stop them [ART pills]." PID
02: patient
Discussion
The effect of traditional medicine use on adherence has
not been widely reported. In this setting, traditional med-
icine use appeared to affect adherence negatively. Patients
reported that both clinic providers and traditional healers
advised them not to "mix" ART with traditional medi-
cines, leading to ART interruptions. Given that traditional
medicine use is common in this setting [23], a deeper
understanding and clarification to providers of how to
counsel patients on the use of traditional medicines while
on ART is critical.
A key and, to our knowledge, novel finding of our study is
that doubt about the existence of HIV disease, own HIV-
infected status, or both were reported to inhibit adher-
ence. In contrast, an earlier study in an urban setting in
South Africa indicated that a high proportion of partici-
pants had correct knowledge of HIV [12]. This difference
in findings perhaps reflects that the earlier study was con-
ducted in an urban setting where traditional beliefs con-
cerning disease causation may be less common.
Results from a pilot quantitative study conducted among
69 patients in this clinic subsequently confirmed that lack
of belief in HIV disease or in own status was prevalent.
The study showed that 19% patients were uncertain or did
not believe that HIV existed, while 24% were uncertain or
did not believe that they were HIV-infected [24]. This is
despite patients receiving at least three intensive counsel-
ling sessions on HIV and ART prior to starting treatment.
To what degree this factor truly affects adherence to ART is
not yet clear and is being further investigated. Meanwhile,
there is a need to find effective ways to support adherence
to ART even if the individual does not accept biomedical
concepts of HIV disease.
No consistent association has been found in low income
countries between level of education and poor adherence
[8,25-27]. However, in this setting providers reported that
lower levels of education were strongly related to poor
adherence, a view not shared by patients interviewed. In a
multilingual setting it may be possible that having less
education is related to speaking a different language from
that of providers, a factor which has previously been
found to be related to poor adherence in South Africa
[28]. The extent to which education affects adherence in
this population, if at all, is not yet clear. However, provid-
ers' perceptions that illiterate patients have a poorer abil-
ity to adhere may have important implications for how
they interact with and provide counselling to patients
with less education. This may also be important in other
ethnically and linguistically diverse African countries
where communication barriers between patients and pro-
viders may negatively affect adherence.
Few studies in the existing literature have examined the
relationship between adherence and health system fac-
tors. Among those that did, cost was found to be the fore-
most reason for poor adherence [13,14]. This was not a
barrier in this setting as a stable and free supply of treat-
ment was available to all patients. However, long waiting
times for clinic services were reported as an important bar-BMC Public Health 2008, 8:63 http://www.biomedcentral.com/1471-2458/8/63
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rier to a patient's ability to return to the clinic for service
and to pick up medication. This might be especially stig-
matizing in this working population as spending addi-
tional time in the clinic may require additional time off
work. Further research is warranted into health system fac-
tors potentially affecting adherence.
Finally, consistent with previously published research in
low-income settings, drug side-effects, alcohol use, being
away from usual place of residence and fear of stigma were
thought to contribute to poor adherence in this setting
[19,20]. In contrast, having social support, a strong belief
in the value of treatment and the ability to fit ART into
daily routines were reported as facilitators of adherence
[16,18]. Interestingly, most patients, even those who were
not completely adherent, reported having some social
support and/or belief in the value of treatment. However,
these alone did not seem to ensure complete adherence.
This suggests that in this setting careful consideration of
multifaceted interventions to promoting adherence is
important.
In our study we purposively sampled a relatively small
number of individuals who were not intended to be rep-
resentative of the clinic population, and our results may
not be generalisable. The study was designed to identify
potential barriers to adherence relevant to this setting,
using in-depth interviews and taking various perspectives
into account. Specifically, by complementing patient
information with provider information we were able to
describe a more complete picture of adherence issues.
There was great congruency between factors mentioned by
the patients and by the providers, to the extent that after
interviewing 12 participants, we felt we had reached satu-
ration of findings. We are currently conducting a much
larger quantitative study that investigates the prevalence
of these barriers in the population, and their association
with poor adherence. However further work is needed to
establish whether these factors are also associated with
poor adherence in other populations The study setting,
among mostly male participants involved in a workplace
ART programme, may also limit generalisability. However
issues related to uncertainty about western biomedical
concepts may arise in other populations, particularly
those where traditional, non-western concepts concerning
illness are prevalent.
Given the above limitations, our data highlight novel bar-
riers to adherence that merit further study in populations
where traditional beliefs around disease causation are
common. Our data also illustrate the value of formative
qualitative research in identifying culturally-relevant bar-
riers to adherence, particularly given the paucity of such
studies in low-income countries [12].
Conclusion
Uncertainty about the existence of HIV disease and use of
traditional medicines while on ART was reported despite
a programme emphasising ART counselling. Thus there is
a need to find effective ways to support adherence to ART
even if the individual does not accept biomedical con-
cepts of HIV disease or decides to use traditional medi-
cines. Additionally, providers should identify ways to
minimize barriers in communication with patients who
speak different languages. Finally, dissatisfaction with
clinical services, namely due to long waiting times, should
be addressed.
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